The global immunotherapy drugs market is expected to witness a CAGR of 12.5% to reach revenue of $215.6 billion by 2025

Bangalore, India, April 29, 2019: With its recently published study “Global Immunotherapy Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025”, Infoholic Research forecasts that the global immunotherapy drugs market will continue to grow, owing to increasing incidence of lifestyle-related and chronic disease globally, increasing product approvals, rising healthcare expenditures, and increasing access to better diagnostic & treatment facilities. High preference for immunotherapy over traditional chemotherapy and its use in combination with the same in first-line treatments coupled with high adoption of targeted therapies is expected to support the market growth during the forecast period 2019–2025.

The immunotherapy drugs market, by type of drug, is segmented into monoclonal antibodies (mAbs), vaccine, non-specific immunotherapies, adaptive cell therapy, and others. Among these, monoclonal antibodies occupied a significant share in 2018 while the fastest growing type was adaptive cell therapy, which is expected to grow at a high CAGR during the forecast period 2019–2025. Increased preference for mAbs with fewer side-effects made this type the dominant market shareholder in 2018.

Get a sample copy of the report @ https://www.infoholicresearch.com/request-a-sample-report/?repid=13288

With respect to therapeutic segments, the immunotherapy drugs market is segmented into cancer, inflammatory and autoimmune disease, infectious disease, and others. Cancer occupied a significant share in 2018 and is expected to grow at a high CAGR during the forecast period 2019–2025. Increasing incidence of leading types of cancers across the world and rising preference & approvals of immunotherapy as a first line of treatment for many cancers have made the oncology segment the number one contributor to the immunotherapy drug sales, followed by key immunological indications such as RA/IJRA, Psoriasis, Ulcerative Colitis, and Crohn’s disease.

The global immunotherapy drugs market, by region, is segmented into North America, Europe, Asia Pacific, and Rest of the World. North America occupied a significant market share in 2018, and Asia Pacific is expected to grow at a high CAGR during the forecast period. Increasing lifestyle-related disorders, rising adoption of novel treatment, increasing healthcare expenditure, and increasing cancer cases make Asia Pacific the fastest growing region during the forecast period.

Access Full Report Summary @ https://www.infoholicresearch.com/report/immunotherapy-drugs-market

“Currently, the immunotherapy drugs market is growing steadily due to increasing adoption of targeted immunotherapies and high preference for the therapy in the initial treatment. The major companies in the market are obtaining extended approval for their key drugs, which is expected to strengthen their position in the market. For instance, in April 2019, Merck & Co. announced the FDA approval of expanded monotherapy label for its KEYTRUDA, as monotherapy for the first-line treatment of patients with stage-III non-small cell lung cancer (NSCLC).” – Arpitha Shetty, Research Analyst, Infoholic Research

Key Insights of the Report Include:

• By Drug Type:
  
  
  
  • Monoclonal Antibodies
  
  
  • Vaccine
  
  
  • Non-specific Immunotherapies
  
  
  • Adaptive Cell Therapy
  
  
  • Others
  
  
  
  


• By Treatment Area:
  
  
  
  • Cancer
  
  
  • Inflammation and Autoimmune Disease
  
  
  • Infectious Disease
  
  
  • Others
  
  
  
  


• By Regions:
  
  
  
  • North America
  
  
  • Europe
  
  
  • Asia Pacific
  
  
  • Rest of the World
  
  
  
  


• Industry outlook: Market trends, drivers, restraints, and opportunities

Contact: